abstract: A Prospective Study on the Efficacy of Octreotide in the Management of Malignant Bowel Obstruction in Gynecologic Cancer

A Prospective Study on the Efficacy of Octreotide in the Management of Malignant Bowel Obstruction in Gynecologic Cancer:

Objective:
Malignant bowel obstruction (MBO), of which symptoms lead to a poor quality of life, is a common and distressing clinical complication in advanced gynecologic cancer. The aim of this study was to prospectively assess the clinical efficacy of octreotide to control vomiting in patients with advanced gynecologic cancer with inoperable gastrointestinal obstruction.

Results: .....No major adverse events related to octreotide were reported.

Conclusions: We conclude that 300-[mu]g/d dose of octreotide was effective and safe for Japanese patients with MBO by advanced gynecologic cancer. Octreotide could contribute to better quality of life by avoiding placement of nasogastric tube.

IGCS and ESGO

full free access: Malignant bowel obstruction: Individualized treatment near the end of life

Key points

Combinations of analgesics, antisecretory drugs, and antiemetics can provide acceptable symptom relief.

A venting gastrostomy should be considered if drug therapy fails to reduce nausea and vomiting to an acceptable level.

A nasogastric tube should be used only as a temporizing measure, until symptoms are controlled medically or a venting gastrostomy is placed.

Total parenteral nutrition is beneficial only in patients with intermediate life expectancy who may otherwise die of starvation rather than the cancer itself.

Multicenter Prospective Study on Efficacy and Safety of Octreotide for Inoperable Malignant Bowel Obstruction

Note: Octreotide(brand name Sandostatin)